跳至主要内容
临床试验/NCT00321217
NCT00321217Unknown不适用

Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis

Radboud University Medical Center3 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2004年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
700
试验地点
3

研究概览

简要总结

The main aim of this study is to identify genetic markers (at DNA and RNA level) which are involved in the response to treatment with monoclonal antibodies against TNF in patients with rheumatoid arthritis.

详细描述

Rheumatoid Arthritis (RA) is a severe inflammatory disease and genetic factors are known to play an important role in its pathogenesis. Genetic factors are also involved in determining the prognosis of RA. Identifying the genetic factors that predispose to mild or aggressive RA is not easy and up to now only a few of these factors -like certain HLA-DR species- are known.

The Rheumatology department of the Radboud University Nijmegen Medical Centre (RUNMC) has collected a unique inception cohort of over 500 patients with RA, that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity, joint damage and other characteristics of disease progression.

In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activity/progression.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with RA according to the ACR criteria who are treated with monoclonal anti-TNF antibodies.

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验